What do systematic reviews say?

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

The review found no eligible studies for this question.

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 0.48 [0.23, 1.01]
  1 study · 34 participants
  Low

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 46 participants
  Very low

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).

• Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 0.89 [0.06, 13.08]
  3 studies · 104 participants
  Very low